Nicolas Margot

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

HIV-1

Physiology

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Svarovskaia Evguenia S; Feng Joy Y; Margot Nicolas A; Myrick Florence; Goodman Derrick; Ly John K; White Kirsten L; Kutty Nilima; Wang Ruth; Borroto-Esoda Katyna; Miller Michael D
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Svarovskaia Evguenia S; Margot Nicolas A; Bae Andrew S; Waters Joshua M; Goodman Derrick; Zhong Lijie; Borroto-Esoda Katyna; Miller Michael D
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
Marchand Bruno; White Kirsten L; Ly John K; Margot Nicolas A; Wang Ruth; McDermott Martin; Miller Michael D; Götte Matthias
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Nicolas Margot (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Svarovskaia Evguenia S; Feng Joy Y; Margot Nicolas A; Myrick Florence; Goodman Derrick; Ly John K; White Kirsten L; Kutty Nilima; Wang Ruth; Borroto-Esoda Katyna; Miller Michael D
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Journal of acquired immune deficiency syndromes (1999) 2008;48(4):428-36.
2007: Svarovskaia Evguenia S; Margot Nicolas A; Bae Andrew S; Waters Joshua M; Goodman Derrick; Zhong Lijie; Borroto-Esoda Katyna; Miller Michael D
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
Journal of acquired immune deficiency syndromes (1999) 2007;46(2):174-80.
2007: Marchand Bruno; White Kirsten L; Ly John K; Margot Nicolas A; Wang Ruth; McDermott Martin; Miller Michael D; Götte Matthias
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
Antimicrobial agents and chemotherapy 2007;51(8):2911-9.
2007: Chappell Brandi J; Margot Nicolas A; Miller Michael D
Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.
AIDS (London, England) 2007;21(6):761-3.
2007: Miller Michael D; Margot Nicolas; McColl Damian; Cheng Andrew K
K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.
AIDS (London, England) 2007;21(2):265-6.
2007: Ly John K; Margot Nicolas A; MacArthur Holly L; Hung Magdeleine; Miller Michael D; White Kirsten L
The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
Antiviral chemistry & chemotherapy 2007;18(6):307-16.
2006: Margot N A; Waters J M; Miller M D
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
Antimicrobial agents and chemotherapy 2006;50(12):4087-95.
2006: Margot N A; Lu B; Cheng A; Miller M D;
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
HIV medicine 2006;7(7):442-50.
2006: White Kirsten L; Chen James M; Feng Joy Y; Margot Nicolas A; Ly John K; Ray Adrian S; Macarthur Holly L; McDermott Martin J; Swaminathan S; Miller Michael D
The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.
Antiviral therapy 2006;11(2):155-63.
2006: Feng Joy Y; Myrick Florence T; Margot Nicolas A; Mulamba Gilbert B; Rimsky Laurence; Borroto-Esoda Katyna; Selmi Boulbaba; Canard Bruno
Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Nucleosides, nucleotides & nucleic acids 2006;25(1):89-107.
2005: White Kirsten L; Margot Nicolas A; Ly John K; Chen James M; Ray Adrian S; Pavelko Martina; Wang Ruth; McDermott Martin; Swaminathan S; Miller Michael D
A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.
AIDS (London, England) 2005;19(16):1751-60.
2005: Margot Nicolas A; Miller Michael D
In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.
Antiviral therapy 2005;10(2):343-8.
2004: McColl Damian J; Margot Nicolas A; Wulfsohn Michael; Coakley Dion F; Cheng Andrew K; Miller Michael D
Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.
Journal of acquired immune deficiency syndromes (1999) 2004;37(3):1340-50.
2004: White Kirsten L; Chen James M; Margot Nicolas A; Wrin Terri; Petropoulos Christos J; Naeger Lisa K; Swaminathan S; Miller Michael D
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
Antimicrobial agents and chemotherapy 2004;48(3):992-1003.
2004: Miller Michael D; Margot Nicolas; Lu Biao; Zhong Lijie; Chen Shan-Shan; Cheng Andrew; Wulfsohn Michael
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
The Journal of infectious diseases 2004;189(5):837-46.
2003: Margot Nicolas A; Isaacson Erica; McGowan Ian; Cheng Andrew; Miller Michael D
Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
Journal of acquired immune deficiency syndromes (1999) 2003;33(1):15-21.
2002: White Kirsten L; Margot Nicolas A; Wrin Terri; Petropoulos Christos J; Miller Michael D; Naeger Lisa K
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
Antimicrobial agents and chemotherapy 2002;46(11):3437-46.
2002: Naeger Lisa K; Margot Nicolas A; Miller Michael D
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.
Antimicrobial agents and chemotherapy 2002;46(7):2179-84.
2002: Margot Nicolas A; Isaacson Erica; McGowan Ian; Cheng Andrew K; Schooley Robert T; Miller Michael D
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
AIDS (London, England) 2002;16(9):1227-35.
2001: Miller M D; Margot N A; Lamy P D; Fuller M D; Anton K E; Mulato A S; Cherrington J M
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Journal of acquired immune deficiency syndromes (1999) 2001;27(5):450-8.
2001: Naeger L K; Margot N A; Miller M D
Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Antiviral therapy 2001;6(2):115-26.
2001: Naeger L K; Margot N A; Miller M D
Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine.
Nucleosides, nucleotides & nucleic acids 2001;20(4-7):635-9.
2000: Van Rompay K K; Miller M D; Marthas M L; Margot N A; Dailey P J; Canfield D R; Tarara R P; Cherrington J M; Aguirre N L; Bischofberger N; Pedersen N C
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Journal of virology 2000;74(4):1767-74.
1999: Wainberg M A; Miller M D; Quan Y; Salomon H; Mulato A S; Lamy P D; Margot N A; Anton K E; Cherrington J M
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
Antiviral therapy 1999;4(2):87-94.
1998: Miller M D; Lamy P D; Fuller M D; Mulato A S; Margot N A; Cihlar T; Cherrington J M
Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.
Molecular pharmacology 1998;54(2):291-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Nicolas Margot

Research Profile (preview)

Chemicals & Drugs

Living Beings

Physiology

Disorders

Procedures

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Nicolas Margot (preview)

All Publications